HYBIO(SZ:300199) Xin Lang Cai Jing·2025-08-24 06:40Core Viewpoint - The company reported strong financial performance for the first half of 2025, with significant revenue and profit growth driven by international expansion and improved operational efficiency [1] Financial Performance - In 2025 H1, the company achieved revenue of 549 million yuan (+114.86%) and a net profit attributable to shareholders of 145 million yuan (+1504.3%), with a non-recurring net profit of 123 million yuan (+306.59%) [1] - For Q2 2025, revenue reached 239 million yuan (+127.07%), net profit attributable to shareholders was 76 million yuan (+1919.66%), and non-recurring net profit was 58 million yuan (+232.49%) [1] - The company's international business revenue was 425 million yuan (+272.76%), accounting for 77.40% of total revenue, up from 55.1% in 2024 [1] Business Segments - Peptide Formulations: The company is expanding its product matrix and promoting international commercialization of existing products, with 18 varieties passing or deemed equivalent to consistency evaluation [2] - API (Active Pharmaceutical Ingredients): The company is actively pursuing international market expansion, with new production capacities ramping up. As of 2025 H1, the Wuhan subsidiary obtained 33 production licenses for peptide APIs [3] - Small Nucleic Acids: The company is positioning itself to benefit from the growing demand for small nucleic acid drugs, with ongoing development of related products and capacities [3] - CRDMO (Contract Research, Development, and Manufacturing Organization): The company has achieved international certifications and is expanding its CRDMO services to provide a comprehensive offering to global clients [3] Future Outlook - The company anticipates revenue growth from 1.099 billion yuan in 2025 to 1.941 billion yuan in 2027, with corresponding net profits expected to rise from 273 million yuan to 576 million yuan [4]